A Phase 1 Open-Label, Dose Escalation Study Evaluating the Safety and Tolerability of IPI-493 in Patients Experiencing Advanced Hematologic Malignancies with Client Proteins of Hsp90.

Trial Profile

A Phase 1 Open-Label, Dose Escalation Study Evaluating the Safety and Tolerability of IPI-493 in Patients Experiencing Advanced Hematologic Malignancies with Client Proteins of Hsp90.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 23 Apr 2015

At a glance

  • Drugs IPI 493 (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Myelofibrosis; Myeloproliferative disorders
  • Focus Adverse reactions
  • Sponsors Infinity Pharmaceuticals
  • Most Recent Events

    • 10 Jun 2011 Planned End Date changed from 1 Oct 2011 to 1 Jul 2011 as reported by ClinicalTrials.gov.
    • 10 Jun 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 31 Aug 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top